Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease.
H
untington's disease (HD) is an inherited progressive neurological disorder caused by a CAG͞polyglutamine (polyQ) expansion and is associated with selective cell death and the deposition of polyQ aggregates in the brain (1) . Recent studies suggest that transcriptional dysregulation might play a role in HD pathogenesis (2) (3) (4) by decreasing several functions including histone acetyltransferase and Sp1 and TAFII130 activity (5) (6) (7) (8) (9) (10) (11) (12) (13) . Although the molecular basis of transcriptional dysfunction in HD requires further dissection, transcriptional repression is the predominant result of dysregulation.
Histone deacetylases (HDACs) work in concert with histone acetyl transferases to modify chromatin and regulate transcription (14) . HDAC inhibitors such as trichostatin A and suberoylanilide hydroxamic acid (SAHA) have been shown to act selectively on gene expression and are potent inducers of growth arrest, differentiation, and͞or apoptotic cell death of transformed cells in vitro and in vivo (15) (16) (17) (18) . Recent studies in cell culture, yeast, and Drosophila models of polyQ disease have indicated that HDAC inhibitors might provide a useful class of agents to ameliorate the transcriptional changes in HD (9) (10) (11) . For example, alleviation of transcriptional repression in Drosophila models either by genetic reduction of Sin3A corepressor activity or through administration of HDAC inhibitors was shown to rescue lethality and photoreceptor neurodegeneration (11) .
Therapeutic trials in humans are challenging, because of the late onset, variability, and slow progression of HD. Therefore, before testing novel therapeutics in clinical trials, compounds must be rigorously and extensively evaluated in genetic HD mouse models, a wide range of which are now available (19) . The R6͞2 line (20, 21) has been used the most extensively for preclinical trials (22) (23) (24) (25) . The early onset of impairment (5-6 weeks), rapid progression of the disease (severely impaired at 12-14 weeks), and reproducibility of the phenotype makes it particularly suitable for this type of study.
Here we ask whether the beneficial effects of HDAC inhibitors in Drosophila models of polyQ disease can be reproduced in preclinical mouse trials. We show that SAHA can cross the blood-brain barrier and demonstrate bioactivity in brain tissue. SAHA has an effective concentration of Ϸ2.5 M and is relatively insoluble in aqueous solution. We show that when complexed with 2-hydroxypropyl-␤-cyclodextrin (HOP-␤-CD), we are able to administer SAHA in drinking water and dramatically improve motor impairment in the R6͞2 mouse model.
Methods
Drug Formulation. SAHA (Aton Pharma) was solubilized in 5 molar equivalents of HOP-␤-CD (ICN) in water. In the main trial, 0.67 g of SAHA was added to a solution of 18 g of HOP-␤-CD in 1 liter of water, heated until fully dissolved, and rapidly cooled on ice to room temperature. This solution was administered to the mice in place of drinking water and replaced weekly. SAHA solutions of various concentrations were prepared by maintaining the molar ratio between SAHA and HOP-␤-CD. Placebo was an equivalent concentration of HOP-␤-CD without SAHA.
Animals. Affected mice were hemizygous R6͞2 females (20) [available from the Induced Mutant Resource, The Jackson Laboratory, code B6CBA-TgN (HDexon1)62] bred and reared in our colony by backcrossing R6͞2 males to C57BL͞6 ϫ CBA F 1 females. Transgenic animals were identified before weaning by PCR of tail-tip DNA, and CAG repeat size was determined (26) . Control mice were WT female littermates. Mice were weaned into their treatment groups at 4 weeks of age. All animals had unlimited access to rodent breeding chow (Special Diet Services, Witham, U.K.) from a food hopper and placebo or drug solution. From age 12 weeks, all animals were additionally given mash consisting of powdered chow mixed with the drug solution as given in the drinking bottle. The mice were subject to a 12-h light (08:00-20:00), 12-h dark (20:00-08:00) cycle. Living conditions and baseline characteristics of study groupings were rigorously standardized.
Organotypic Slice Culture Assay. Organotypic hippocampal slice cultures were established as described (27) . SAHA in HOP-␤-CD solution was added to the culture medium from day 1 until the termination of the experiment at concentrations from 0.025 to 250 M, and HOP-␤-CD and media controls were included. We established that HOP-␤-CD has no effect on polyQ aggregation over a 5-log concentration range (data not shown), and therefore the HOP-␤-CD concentration required to complex 250 M was used as the vehicle in this experiment. The medium was changed twice weekly, and slices were fixed at weekly intervals from 2 weeks in culture. The huntingtin aggregate load was assessed by quantitative indirect immunofluorescence (27) , and results were analyzed by using the general linear model ANOVA with false discovery rate correction (28) .
Behavioral Analysis. Rotarod impairment was assessed on a Ugo Basile 7650 accelerating Rotarod (Linton Instrumentation, Diss, U.K.), modified as described (29) . Animals (R6͞2: n ϭ 13, WT: n ϭ 12 per treatment group) were tested at 4 weeks of age to establish their baseline performance and again at 8, 10, and 12 weeks of age. Grip strength was measured once per fortnight (29) , and animals were weighed weekly to the nearest 0.1 g. Statistical analysis of grip strength used ANOVA on the mean grip strength. Rotarod data were analyzed at each time point by using repeated measures in a linear mixed effects model (in S-plus).
Antibodies, Western Blotting, Histology, and Immunohistochemistry.
Antibodies were as follows: huntingtin exon 1 protein (S830) (30) ; ubiquitin (DAKO); acetylated histone H2A (Lys-5) and acetylated histone H2B (Serotec); and acetylated histone H3 and acetylated histone H4 (Upstate Biotechnology, Lake Placid, NY). Histones were isolated from whole brain, and Western blots for histone acetylation (31) were as published. Brains for histology and immunohistochemistry were frozen in isopentane and stored at Ϫ80°C until required, and 15-m sections were cut by using a cryostat (Bright Instrument, Huntingdon, U.K.). Immunohistochemistry was performed as described (27) . Nissl staining was carried out by standard protocols (32) , with the exception that frozen sections were postfixed in 4% paraformaldehyde for 30 min and washed in TBS (50 mM Tris⅐HCl, pH 7.5͞0.9% NaCl) before staining.
Real-Time RT-PCR Analysis. RNA was prepared from whole brain by using the RNeasy mini kit (Qiagen, Crawley, U.K.) according to the manufacturer's recommendations. Real-time PCR was performed as described (33) by using the ABI Prism 7700 (Perkin-Elmer-Applied Biosystems). R6͞2 transgene primers were: GCTGCACCGACCGTGAGT (forward), CAGGCTG-CAGGGTTAC (reverse), and CAGCTCCCTGTCCCGGCGG (probe). Abl primers were: CAAATCCAAGAAGGGGCTCTCT (forward), TCGAGCTGCTTCGCTGAGA (reverse), and CCCT-GCAGAGGCCAGTGGCATCT (probe).
Results

SAHA Crosses the Blood-Brain Barrier and Increases Histone Acetylation in Brain.
Our initial experiments sought to determine whether SAHA crosses the blood-brain barrier. SAHA is relatively insoluble in aqueous solutions, and in previous mouse efficacy studies (31) , it had been administered at doses up to 100 mg͞kg i.p. in 100% DMSO or orally in the diet (34) . The parenteral mode of administration was likely to be impractical in an efficacy study that required daily dosing, as DMSO is not well tolerated on repeated injection. Therefore, alternative vehicles for SAHA delivery were investigated and we found that SAHA is capable of forming a complex with HOP-␤-CD with greatly enhanced aqueous solubility.
Increased levels of histone acetylation resulting from i.p. (a) To determine the maximum dose of SAHA, which when complexed with HOP-␤-CD could be administered to WT mice in drinking water, a dose escalation strategy was used (Table 1) . Our initial intention was to assess the tolerability of 2.67 g͞liter (400 mg͞kg) and 4 g͞liter (600 mg͞kg). (b) Doses of 2.67 g͞liter SAHA and above caused dramatic weight loss. On lowering the dose from 3.33 g͞liter to 2 g͞liter (300 mg͞kg), the formulation was well tolerated.
injection of 50 mg͞kg SAHA are readily detected in tumor tissue (31) . To determine whether comparable levels of acetylation are apparent in brain, either 100 mg͞kg or 200 mg͞kg SAHA in HOP-␤-CD was administered to WT and R6͞2 mice by a single s.c. injection, and brain and spleen samples were taken 2, 3, and 6 h after drug administration. For comparison, 100 mg͞kg SAHA in either HOP-␤-CD or DMSO was administered to WT and R6͞2 by single i.p. injection. We found no difference in the degree of histone acetylation between untreated WT and R6͞2 mice. Significant increases in histone acetylation could be detected only on s.c. administration of 200 mg͞kg (Fig. 1) . Administration of SAHA dramatically increased acetylation of histones H2B and H4 2 h postinjection (Fig. 1) ; this increase was maintained at 3 h and had diminished by 6 h (data not shown).
With this regimen, increases in histone acetylation were similar in the brain and spleen and comparable between WT and R6͞2 mice. Therefore, SAHA is able to cross the blood-brain barrier and mount a biological response.
SAHA Can Be Administered in Drinking Water. We had observed increases in histone acetylation in brain tissue after s.c. administration of 200 mg͞kg SAHA in HOP-␤-CD. However, at the concentration required to achieve SAHA dosages of 100-200 mg͞kg by injection, the cyclodextrin vehicle was viscous and difficult to handle. Therefore, we aimed to administer 200 mg͞kg SAHA in HOP-␤-CD in drinking water. Assuming that a 20-g mouse drinks 3 ml͞day (35) , this corresponds to a dose of 1.33 g͞liter. Using a dose escalation strategy (Fig. 2a, Table 1 ), we found that we could administer oral doses of up to 2 g͞liter in WT mice for up to 3 weeks starting at 6-7 weeks of age without significant weight loss or other adverse effects (Fig. 2b) . However, application of this dosing regime to R6͞2 mice resulted in weight loss, and one mouse (of four) died within 1 week. R6͞2 mice on the HOP-␤-CD placebo concentration corresponding to the 2 g͞liter SAHA dose suffered no adverse effects, and R6͞2 mice receiving up to 1.33 g͞liter SAHA also showed no adverse symptoms (data not shown).
We therefore initiated an eight-arm efficacy trial comprising two drug (0.67 g͞liter and 1.33 g͞liter SAHA in HOP-␤-CD) and two placebo arms (the corresponding HOP-␤-CD concentrations) for WT and R6͞2 mice. Drug administration commenced at 30 days of age after an initial testing week, which was used to sort the mice into well-matched treatment groups (Fig. 3a) . Similarly, the CAG repeat size of the R6͞2 mice was well matched at 200 Ϯ 4 (SD). Unexpectedly, given the results of our pilot studies, both WT and R6͞2 mice on 1.33 g͞liter SAHA failed to gain weight, and after 2 weeks, weighed Ͼ20% less than mice on the corresponding placebo (data not shown). In addition, 2͞12 WT and 2͞13 R6͞2 mice in this study arm died at Ϸ6 weeks of age. Therefore, we terminated the 1.33 g͞liter SAHA and placebo arms of the experiment and proceeded only with the 0.67 g͞liter and corresponding placebo groups.
SAHA Improves Motor Impairment in R6͞2 Mice. The effect of SAHA administration on the R6͞2 phenotype was assessed by Rotarod analysis of motor impairment, grip strength, and failure to gain weight. R6͞2 mice treated with 0.67 g͞liter SAHA showed a strong and consistent improvement in Rotarod performance as compared with those on placebo (Fig. 3b) . The regression of mean latency times at weeks 8, 10, and 12 showed a highly significant difference between R6͞2 mice on placebo and R6͞2 mice on SAHA (P ϭ 0.0009). There were no significant differences in performance of SAHA-treated WT mice compared with WT mice on placebo (Fig. 3b) . The performance of both WT and R6͞2 mice on placebo was consistent with findings from recent experiments by using the same protocol at all time points (R6͞2: 8 weeks, 141-148 s; 12 weeks, 55-77 s) (WT: 8 weeks, 250-288 s; 12 weeks, 230-262 s). In contrast, the mean performance of R6͞2 mice on SAHA from 8 weeks was well above the upper limit from all previous tests.
We found no significant difference in mean grip strength (Fig.  3c ) between treated and placebo mice of either genotype at any age. WT mice in both treatment arms performed significantly better than R6͞2 mice at 12 weeks of age (placebo: P Ͻ 10 Ϫ5 ; SAHA, P Ͻ 0.02). SAHA did not prevent the failure of R6͞2 mice to gain weight (Fig. 3d) . R6͞2 mice were Ϸ20% lighter than WT mice at 13 weeks in both treatment groups. However, both WT and R6͞2 mice treated with SAHA failed to gain weight to the same extent as their littermates taking the placebo control (both Ϸ18% at 13 weeks compared with appropriate placebo group). If this additional weight loss is caused by marginal toxicity of SAHA, it seems that there is no interaction with genotype: WT and R6͞2 mice are equally affected. By regression analysis, weight was a significant positive predictor of mean grip strength in R6͞2 (P ϭ 0.015), but not in WT (P ϭ 0.229) mice at 12 weeks of age. Entering both weight and treatment received into a multiple regression model revealed an improvement in grip strength at 12 weeks in R6͞2 (P ϭ 0.012) but not in WT (P ϭ 0.810) mice treated with SAHA.
Effects of SAHA on Gross and Cellular Brain Morphology. Examination of Nissl-stained brain sections revealed no overt difference in gross morphology between WT and R6͞2 mice treated with either SAHA or placebo (Fig. 4a) . Although the R6͞2 mean brain weight was significantly less than WT (Student's t test: R6͞2, 0.396 g; WT, 0.447 g; P ϭ 0.01), there was no difference by regression analysis between mice treated with SAHA or placebo (P ϭ 0.777). Similarly, there was no correlation with body weight within each genotype (P ϭ 0.243).
Examination of the Nissl-stained sections under higher power revealed cellular atrophy in the R6͞2 striatum as compared with WT (Fig. 4b) as documented (22) . Treatment of R6͞2 mice with SAHA resulted in Nissl staining more closely resembling that in WT mice.
SAHA Does Not Inhibit PolyQ Aggregation. To rule out that SAHA might exert its effects through the inhibition of polyQ aggregation, its ability to act as an aggregation inhibitor was tested in an organotypic slice culture assay (27) . We have developed this technique to bridge the gap between wholly in vitro aggregation assays and preclinical trials and allow us to quantify aggregate formation in a system in which aggregates form at the same rate and in the same sequence as they do in vivo. Hippocampal slices were established from R6͞2 neonates at P7 and cultured in the presence of SAHA complexed with HOP-␤-CD at concentrations ranging from 0.025 to 250 M over a period of 4 weeks. Concentrations of 25 and 250 M proved toxic. After 3 and 4 weeks there was no difference in the aggregate load between slices cultured in 0.025, 0.25, or 2.5 M SAHA as compared with vehicle control (Fig. 5a) . By a less quantitative immunohistochemical approach, no treatment-related differences in aggregate load were detected by using either antihuntingtin or antiubiquitin antibodies to immunoprobe sections of postmortem brains from R6͞2 mice (Fig. 5b.) .
SAHA Does Not Down-Regulate the R6͞2 Transgene. To ensure that SAHA is not acting directly on the transgene promoter to down-regulate the R6͞2 transgene, RNA was prepared from the brains of R6͞2 mice that had been treated with either 0.67 g͞liter SAHA or placebo for 17 days. Experiments were performed in triplicate, and the number of real-time PCR products was determined for the R6͞2 transgene by using the c-abl oncogene as control (Fig. 5c ). There is no difference in the level of expression of the R6͞2 transgene (P ϭ 0.92) or c-abl (P ϭ 0.69) between SAHA-and placebo-treated mice.
Discussion
HDAC inhibitors have been shown to reduce polyQ toxicity in a Drosophila model of HD (11) . We now show that the potent HDAC inhibitor, SAHA, dramatically improves Rotarod performance in the R6͞2 HD mouse model. R6͞2 mice treated with 0.67 g͞liter SAHA demonstrated a significant improvement at 8 weeks of age after only 3 weeks of drug administration. At 12 weeks, the R6͞2 mice taking SAHA were performing as well as the placebo group did at 8 weeks, indicating a delay by as much as 1 month in the decline in Rotarod performance. These results are yet more impressive given that our mice were housed in environmentally enriched conditions, which alone improved the Rotarod performance of R6͞2 mice by Ϸ40% of the difference between R6͞2 and WT (29) . Therefore, drugs tested in our preclinical trials must cause significant additional improvement to be registered as effective. Our demonstration that SAHA treatment in part redresses the loss of striatal Nissl staining suggests that this may represent a neuropathological correlate of motor impairment.
SAHA is a small hydrophobic molecule and its relative insolubility in aqueous solution posed considerable difficulties. To combat this, we determined that SAHA is capable of forming a complex with HOP-␤-CD with greatly enhanced aqueous solubility. Cyclodextrins are doughnut-shaped molecules consisting of six (␣), seven (␤), or eight (␥) glucose units linked by ␣-1,4 glycosidic bonds with their hydrophobic faces innermost. Small hydrophobic molecules can enter the central cavity to form a complex with the cyclodextrin. Because the hydrophilic surfaces of the cyclodextrins face outward, aqueous solubility is imparted on the complexes. Complexation with cyclodextrins can have additional benefits. These include a reduction in drug toxicity and irritation at the site of administration, masking of unpleasant tastes, and alteration of the pharmacokinetic profile of a drug, often increasing the half-life. HOP-␤-CD is a nontoxic semisynthetic cyclodextrin, which is widely used in vitro and in vivo as a drug carrier in both enteral and parenteral formulations (36) .
SAHA did not ameliorate the failure of R6͞2 mice to gain weight, possibly reflecting its narrow therapeutic window with beneficial effects being masked by its toxicity. When SAHA administration was initiated at 30 days, doses Ն1.33 g͞liter were toxic to both WT and R6͞2 mice. Adverse effects were also seen in both WT and R6͞2 mice at the effective dose of 0.67 g͞liter, with mice failing to gain weight at the same rate as placebotreated mice. However, despite this inherent toxicity, no R6͞2 mice or WT mice died before the termination of the experiments at 13 weeks, and maintenance of grip strength in SAHA-treated R6͞2 mice may indicate a sparing of muscle atrophy.
This study corroborates the use of HDAC inhibitors as therapeutic compounds for HD. Our demonstration that SAHA administration increases histone acetylation supports the hypothesis that it acts by redressing transcriptional repression. Although our results demonstrate that the identification of potential therapeutic compounds in Drosophila models can translate to preclinical mouse trials, we would caution against SAHA has no effect on aggregate count, aggregate fluorescence intensity, or aggregate area. Error bars ϭ SD. (b) Immunodetection of polyQ aggregates (arrow) using antibodies raised against huntingtin (S830) and ubiquitin in postmortem brains from R6͞2 mice at 13 weeks of age that had been administered SAHA or placebo for 8 weeks (age 13 weeks). (c) Real-time PCR to determine the level of expression of the R6͞2 transgene and c-abl oncogene. R6͞2 mice (10 -11 weeks) had been treated with 0.67 g͞liter SAHA (n ϭ 7) or placebo (n ϭ 7) for 17 days.
proceeding too rapidly to clinical trials. Demonstration of efficacy with SAHA is particularly encouraging as this drug is Ϸ10 3 fold more potent than the butyrate class of HDAC inhibitors [on a molar basis as an inhibitor of HDAC activity (15) ] that are also under consideration. However, novel hydroxamic acid derivatives with enhanced activity as potential HD therapeutics also should be assessed.
